EVENTS SUBSEQUENT TO REPORTING DATE On 18 October 2017, a final dividend of 3.5 cents per share, fully franked to be paid out of the Profits Reserve on 8 December 2017, amounting to $17.431 million was declared. Other than above, there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the Directors of the Company, to affect significantly the operations of the consolidated entity, the results of those operations or the state of affairs of the consolidated entity in future years. LIKELY DEVELOPMENTS The consolidated entity will continue to pursue its policy of improving the profitability and market share of each of its major operating businesses during the next financial year. Further information regarding the business strategies of the consolidated entity and the expected results of those operations in future financial years have not been included in this report as disclosure of this information would likely result in unreasonable prejudice to the consolidated entity. DIRECTORS’ REPORT CONTINUED For personal use only
Australian Pharmaceutical Industries Limited Annual Report 2017 30 DIRECTORS’ INTERESTS The relevant direct and indirect and beneficial interest of each Director, in the share capital of the Company, as notified by the Directors to the Australian Securities Exchange in accordance with section 205G(1) of the Corporations Act 2001 at the date of this report is as follows: Ordinary Shares Performance Rights over Ordinary Shares Mr P R Robinson 302,168 – Ms E C Holley (ceased being a Director on 25 January 2017) 16,667 – Mr R D Millner 1,755,620 – Mr S P Roche (ceased being a Director on 15 February 2017) 944,674 1,535,551 Ms L Ausburn 83,334 – Mr G J Masters 218,000 – Mr K Gunderson-Briggs 10,000 – Mr R Vincent (appointed a Director on 15 February 2017) 145,444 663,465 PERFORMANCE RIGHTS GRANTED TO DIRECTORS AND OFFICERS OF THE COMPANY Details of the performance rights granted to Directors and officers of the Company are set out in the Remuneration Report. INSURANCE AND INDEMNIFICATION OF DIRECTORS AND OFFICERS During the year the Company paid a premium in respect of a contract insuring the Directors and officers against all liabilities to another person (other than the Company or a related body corporate) that may arise from their position, except where the liability arises out of conduct involving a lack of good faith. The contract covers any past, present or future Director, Secretary, Executive Officer or employee of the Company and its controlled entities. Further details have not been disclosed due to confidentiality provisions of the contract of insurance. The Directors are each parties to a Director’s Access and Insurance Deed. This Deed includes an indemnity by the Company (subject to and to the fullest extent permitted by applicable law) summarised as follows: a. for any liability incurred by the Director as an officer of the Company; b.
- Fall '16
- ........., managing director, Corporate title, Non-executive director